ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Mindpeak Raises $15.3 Million to Revolutionize AI-Powered Cancer Diagnostics

NextEdge Admin

01 Oct 2024

2 min 19 sec

Mindpeak, a leader in AI-powered pathological solutions, has secured $15.3 million in a Series A funding round led by ZEISS Ventures and InnoVentureFund, with participation from AI.FUND and the European Innovation Council Fund. While already operating a cash-flow positive core business, this investment will fuel the company’s expansion into new markets.

“With this capital, we will accelerate the development and deployment of our AI solutions, empowering pathologists with faster, more accurate diagnostic tools,” said Felix Faber, CEO of Mindpeak. “Our aim is to revolutionize cancer diagnostics and ultimately improve patient outcomes.”

Mindpeak’s AI algorithms were among the first to be used for routine clinical diagnostics in the US and EU. Their solutions enable automated histological and immunohistochemical tissue analysis, allowing experts to make more confident decisions. To date, over 30,000 patient diagnoses have been supported using their technology. Additionally, biopharmaceutical companies leverage Mindpeak’s AI to predict medication effectiveness and enable targeted cancer treatments.

Founded in 2018, Mindpeak has quickly become a leader in digital pathology. “We are convinced of Mindpeak’s promising future,” said Mike Gänßler, Investment Manager at ZEISS Ventures.

The company recently expanded its product portfolio to include additional organs, biomarkers, and stainings. Strategic partnerships with healthcare organizations, such as Roche, and positive regulatory developments have further strengthened their market position.

“This funding will solidify Mindpeak as a key player in transforming cancer diagnostics,” said Gencer Sahin, Head of Investments at InnoVentureFund.